BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28905201)

  • 1. Assessment of intratumor heterogeneity in mesenchymal uterine tumor by an
    Tsujikawa T; Yamamoto M; Shono K; Yamada S; Tsuyoshi H; Kiyono Y; Kimura H; Okazawa H; Yoshida Y
    Ann Nucl Med; 2017 Dec; 31(10):752-757. PubMed ID: 28905201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of PET/CT to exclude leiomyoma in patients with lesions suspicious for uterine sarcoma on MRI.
    Kusunoki S; Terao Y; Ujihira T; Fujino K; Kaneda H; Kimura M; Ota T; Takeda S
    Taiwan J Obstet Gynecol; 2017 Aug; 56(4):508-513. PubMed ID: 28805609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma.
    Cheng NM; Fang YH; Chang JT; Huang CG; Tsan DL; Ng SH; Wang HM; Lin CY; Liao CT; Yen TC
    J Nucl Med; 2013 Oct; 54(10):1703-9. PubMed ID: 24042030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral heterogeneity of (18)F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma.
    Hyun SH; Kim HS; Choi SH; Choi DW; Lee JK; Lee KH; Park JO; Lee KH; Kim BT; Choi JY
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1461-8. PubMed ID: 26872788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ability of
    Ou X; Wang J; Zhou R; Zhu S; Pang F; Zhou Y; Tian R; Ma X
    Contrast Media Mol Imaging; 2019; 2019():4507694. PubMed ID: 30930700
    [No Abstract]   [Full Text] [Related]  

  • 6.
    Tsujikawa T; Rahman T; Yamamoto M; Yamada S; Tsuyoshi H; Kiyono Y; Kimura H; Yoshida Y; Okazawa H
    Ann Nucl Med; 2017 Nov; 31(9):678-685. PubMed ID: 28815452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
    Yamane T; Takaoka A; Kita M; Imai Y; Senda M
    Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
    Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
    J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multiparametric MRI-based machine learning to distinguish between uterine sarcoma and benign leiomyoma: comparison with
    Nakagawa M; Nakaura T; Namimoto T; Iyama Y; Kidoh M; Hirata K; Nagayama Y; Oda S; Sakamoto F; Shiraishi S; Yamashita Y
    Clin Radiol; 2019 Feb; 74(2):167.e1-167.e7. PubMed ID: 30471748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating the grades of thymic epithelial tumor malignancy using textural features of intratumoral heterogeneity via (18)F-FDG PET/CT.
    Lee HS; Oh JS; Park YS; Jang SJ; Choi IS; Ryu JS
    Ann Nucl Med; 2016 May; 30(4):309-19. PubMed ID: 26868139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
    Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
    Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Texture analysis of FDG PET/CT for differentiating between FDG-avid benign and metastatic adrenal tumors: efficacy of combining SUV and texture parameters.
    Nakajo M; Jinguji M; Nakajo M; Shinaji T; Nakabeppu Y; Fukukura Y; Yoshiura T
    Abdom Radiol (NY); 2017 Dec; 42(12):2882-2889. PubMed ID: 28612161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional value of 16α-[18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET.
    Yoshida Y; Kiyono Y; Tsujikawa T; Kurokawa T; Okazawa H; Kotsuji F
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1824-31. PubMed ID: 21656049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Tumor Heterogeneity and SUVmax of Pretreatment 18F-FDG PET/CT for Salivary Gland Carcinoma With High-Risk Histology.
    Cheng NM; Hsieh CE; Liao CT; Ng SH; Wang HM; Fang YD; Chou WC; Lin CY; Yen TC
    Clin Nucl Med; 2019 May; 44(5):351-358. PubMed ID: 30932974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status.
    Lovinfosse P; Koopmansch B; Lambert F; Jodogne S; Kustermans G; Hatt M; Visvikis D; Seidel L; Polus M; Albert A; Delvenne P; Hustinx R
    Br J Radiol; 2016 Jul; 89(1063):20160212. PubMed ID: 27146067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Textural features of
    Saleem BR; Beukinga RJ; Boellaard R; Glaudemans AW; Reijnen MM; Zeebregts CJ; Slart RH
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):886-894. PubMed ID: 28013350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
    Kim YI; Cheon GJ; Paeng JC; Cho JY; Kang KW; Chung JK; Kim EE; Lee DS
    Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of
    Albano D; Zizioli V; Treglia G; Odicino F; Giubbini R; Bertagna F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):10-16. PubMed ID: 30396849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of textural analysis parameters derived from FDG PET/CT in differentiating hepatocellular carcinoma and hepatic metastases.
    Ravina M; Mishra A; Kote R; Kumar A; Kashyap Y; Dasgupta S; Reddy M
    Nucl Med Commun; 2023 May; 44(5):381-389. PubMed ID: 36826419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.